J.Sales-Llopis

Neurosurgery Department, General University Hospital Alicante, Spain.

• A zinc transporter drives glioblastoma progression via extracellular vesicles-reprogrammed microglial plasticity
• Genomic, epigenomic and transcriptomic landscape of glioblastoma
• Expression Profile Analysis of Zinc Transporters (ZIP4, ZIP9, ZIP11, ZnT9) in Gliomas and their Correlation with IDH1 Mutation Status

ZIP4 and ZIP11 are promising molecular diagnostic markers and novel therapeutic targets. Nevertheless, the detailed biological function of zinc transporters and the mechanism of the potential interaction between ZIP11 and IDH1 mutation in gliomagenesis should be further investigated ¹⁾

Glioblastoma (GBM), is characterized by an extremely altered glioblastoma genome, which is characterized by the dysregulation of numerous critical signaling pathways and epigenetic regulations associated with proliferation, cellular growth, survival, and apoptosis. In light of this, genetic alterations in critical signaling pathways and various epigenetic regulation mechanisms are associated with GBM and identified as distinguishing markers. Such GBM prognostic alterations are identified in PI3K/AKT, p53, RTK, RAS, RB, STAT3, and ZIP4 signaling pathways, metabolic pathway (IDH1/2), as well as alterations in epigenetic regulation genes (MGMT, CDKN2A-p16INK4aCDKN2B-p15INK4b). The exploration of innovative diagnostic and therapeutic approaches that specifically target these pathways is of utmost importance to enhance future medication for GBM ²⁾

* Overexpressed in GBM cells

• Drives tumor progression by modulating immune microenvironment
• Regulates microglial plasticity via:
  • Extracellular vesicle (EV)-mediated transfer of TREM1
  • Activation of downstream SYK–PDK–STAT3 signaling in microglia
• ZIP4 knockout or inhibition:
  • Reduces tumor growth
  • Attenuates microglia-driven immune support for the tumor

1. ZIP4 increases intracellular zinc in GBM cells
2. Zinc activates ZEB1 (Zinc Finger E-box Binding Homeobox 1)
3. ZEB1 promotes production of TREM1-containing EVs
4. EVs deliver TREM1 to microglia
5. Microglia are reprogrammed via SYK–PDK–STAT3 → tumor-supportive state

• Diseases:
  • Acrodermatitis enteropathica (loss-of-function)
  • Cancers: GBM, pancreatic, prostate, liver (overexpression)
• Therapeutic implications:
  • ZIP4 is a potential oncologic target
  • Inhibition may reduce tumor–immune crosstalk in GBM
  • Strategies may include:
    • Antisense RNA
    • Zinc chelation
    • Targeted inhibition of ZIP4 or its regulatory axis

—-

Zhang et al. present a compelling study identifying the zinc transporter ZIP4 as a driver of glioblastoma progression through a novel tumor–microglia communication mechanism. The authors show that ZIP4 promotes the release of extracellular vesicles (EVs) enriched with TREM1, which reprograms microglial plasticity via the SYK–PDK–STAT3 signalling axis, thereby fostering a pro-tumor immune microenvironment. Targeting ZIP4 or TREM1 dampens tumor growth and behavioral changes in vivo, highlighting a potential therapeutic axis in GBM ³⁾

✅ Strengths Novel Mechanistic Insight:

The study uncovers a previously unknown pathway by which ZIP4 regulates microglial behavior, linking metal ion transport to immune microenvironment modulation, which is conceptually innovative.

Use of Orthotopic GBM Mouse Models:

By using clinically relevant in vivo models, the authors strengthen the translational value of their findings.

Multilevel Approach:

The study spans molecular biology (ZIP4, TREM1, STAT3), cell-cell communication (EVs), and behavioral neuroscience, providing a comprehensive view of tumor-host interaction.

Therapeutic Implication:

Demonstrating that ZIP4 knockdown or TREM1 inhibition reduces tumor progression positions these molecules as realistic drug targets.

Relevance of Microglial Plasticity:

The paper builds on current interest in microglial reprogramming in CNS cancers and contributes mechanistic detail that may inform other pathologies involving neuroinflammation.

⚠️ Limitations and Critical Considerations Limited Human Validation:

While the mouse models are strong, the study lacks a robust analysis of ZIP4/TREM1 axis expression in human GBM tissues across multiple subtypes and patients, limiting direct clinical extrapolation.

Overshadowing Other Zinc Transporters:

The exclusive focus on ZIP4 leaves open whether other SLC39A or SLC30A family members may compensate or synergize, an important aspect for drug resistance or redundancy.

Microglia vs. Macrophages:

The study refers to microglia but does not fully distinguish them from peripheral infiltrating macrophages, which are often phenotypically and functionally entangled in GBM. More precise fate-mapping or single-cell RNA-seq would clarify the cellular target.

Behavioral Outcomes:

The behavioral changes attributed to ZIP4 and TREM1 manipulation are mentioned but not deeply characterized. Given the complexity of CNS behavior, these should be more rigorously validated.

Extracellular Vesicle Specificity:

EV characterization is implied but not thoroughly quantified (e.g., EV subtype, cargo validation, dose-response). This affects the confidence in mechanistic claims regarding TREM1 as the key effector.

Therapeutic Translation:

While TREM1 inhibition shows promise in mice, drug delivery to the brain, toxicity, and specificity remain major hurdles not addressed here.

📌 Overall Significance

This study provides a valuable conceptual advance in understanding how GBM co-opts the innate immune system via zinc metabolism and vesicle-based signaling. It bridges metabolic regulation (ZIP4), vesicular communication, and immune reprogramming in a way that few studies have.

Despite some limitations in translational readiness and experimental scope, the paper is strongly hypothesis-generating and lays the groundwork for:

ZIP4 or TREM1-targeted therapy development

Further exploration of metal-ion-dependent immune modulation in CNS cancers

⭐️ Final Verdict:

A high-impact contribution to neuro-oncology and neuroimmunology that warrants further clinical exploration. Its mechanistic clarity, therapeutic potential, and relevance to microglial plasticity make it a noteworthy study, although deeper validation in human samples and advanced immune profiling are needed for full translational impact.